FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014020560407/24/14 new patent  Antigen binding constructs
22014020566107/24/14 new patent  Formulation for retinoid-containing soft gelatin capsules
32014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
42014019340707/10/14Drug fusions and conjugates
52014018775007/03/14Methods for selecting protease resistant polypeptides
62014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
72014015870406/12/14Medicament dispenser
82014014099605/22/14Anti-serum albumin biding variable domains
92014014099605/22/14Anti-serum albumin biding variable domains
102014011643405/01/14Dry powder inhaler compositions
112014011643405/01/14Dry powder inhaler compositions
122014011292904/24/14Tumour necrosis factor receptor 1 antagonists
132014011388804/24/14Novel combination of therapeutic agents
142014011392204/24/14Compounds
152014011292904/24/14Tumour necrosis factor receptor 1 antagonists
162014011388804/24/14Novel combination of therapeutic agents
172014011392204/24/14Compounds
182014010589404/17/14Humanized anti-il-18 antibodies
192014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
202014010589404/17/14Humanized anti-il-18 antibodies
212014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
222014007631403/20/14Manifold for use in medicament dispenser
232014008086303/20/14Muscarinic acetylcholine receptor antagonists
242014007631403/20/14Manifold for use in medicament dispenser
252014008086303/20/14Muscarinic acetylcholine receptor antagonists
262014005690002/27/14Method for inhibiting binding to b-cell receptor
272014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
282014005071902/20/14Antibodies
292014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
302014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
312014002359601/23/14Novel composition
322014002455801/23/14Method of treatment
332014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
342014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
352013034546512/26/13Process for the preparation of retigabine
362013033698912/19/13Methods of identifying a patient population
372013031590111/28/13Novel uses
382013031704111/28/13Compounds
392013031028111/21/13Novel antigen binding proteins
402013030233511/14/13Ligands that bind tgf-beta receptor ii
412013026771710/10/13Process for the preparation of atovaquone
422013026118510/03/13Benzamide derivatives as ep4 receptor agonists
432013025172409/26/13Antigen binding proteins to oncostatin m (osm)
442013025318809/26/13Novel compounds
452013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
462013022420408/29/13Method of treatment based on atad2 inhibitors
472013022420408/29/13Method of treatment based on atad2 inhibitors
482013021315408/22/13Method of determining cleanliness
492013021339408/22/13Dispensing device
502013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
512013021315408/22/13Method of determining cleanliness
522013021339408/22/13Dispensing device
532013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
542013021089208/15/13Method of treatment
552013021089208/15/13Method of treatment
562013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
572013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
582013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
592013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
602013019641208/01/13Magi polynucleotides, polypetides, and antibodies
612013019641208/01/13Magi polynucleotides, polypetides, and antibodies
622013018925507/25/13Fusions and conjugates of insulinotropic agents
632013018925507/25/13Fusions and conjugates of insulinotropic agents
642013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
652013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
662013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
672013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
682013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
692013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
702013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
712013007819803/28/13Novel use
722013005337502/28/13Amino-quinolines as kinase inhibitors
732013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
742013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
752013003001201/31/13Compounds
762013003001501/31/13Muscarinic acetylcholine receptor antagonists
772013002354101/24/13Voltage-gated sodium channel blockers
782013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
792012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
802012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
812012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
822012028854411/15/12Novel retigabine composition
832012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
842012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
852012024074209/27/12Novel device
862012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
872012023855909/20/12Novel compounds
882012023857109/20/12Indazole derivatives as pi 3-kinase
892012023206109/13/12Novel compounds
902012020774908/16/12Dosing regimen
912012020281108/09/12Novel compounds
922012015744606/21/12Medical use
932012015749106/21/12Muscarinic acetylcholine receptor antagonists
942012015749206/21/12Antibiotic drug
952012014971106/14/12Piperidine derivatives used as orexin antagonists
962012014973106/14/12New medical use
972012012868905/24/12Anti-il-23 immunoglobulins
982012012977805/24/12Ligand that bind tgf-beta receptor rii
992012011464705/10/12 anti-serum album single variable domains
1002012010013704/26/12Immunoglobulins
1012012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
1022012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1032012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1042012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1052012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1062012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1072012005896303/08/12Macrolides with anti-inflammatory activity
1082012004625802/23/12Novel crystalline pharmaceutical product
1092012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1102012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1112012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1122012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1132012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1142012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1152012000632201/12/12Drug dispenser
1162012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1172011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1182011030569212/15/11Antigen-binding contructs
1192011030569312/15/11Anitigen-binding constructs
1202011028809811/24/11Novel compounds
1212011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1222011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1232011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1242011026973811/03/11Compounds
1252011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1262011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1272011025375210/20/11Nozzle for a nasal inhaler
1282011025607410/20/11Novel use
1292011024547010/06/11Immunoglobulins
1302011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1312011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1322011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1332011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1342011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1352011015226206/23/11Novel compounds
1362011014282406/16/11Antibodies against amyloid-beta peptide
1372011014415106/16/11Novel process, salts, composition and use
1382011013569506/09/11Oral dosage form for controlled drug release
1392011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1402011011719005/19/11Pharmaceutical formulations
1412011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1422011006164603/17/11Drug dispenser
1432011006474003/17/11Antigen binding proteins
1442011006572503/17/11Triazole amide derivatives for use in therapy
1452011005916703/10/11Encapsulation of biologically active agents
1462011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1472011004502702/24/11Adjuvant
1482011004613702/24/11Pyrazole derivatives as p2x7 modulators
1492011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1502011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1512011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1522011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1532010032999612/30/10Novel combination of therapeutic agents
1542010032402212/23/10Novel compounds
1552010031657912/16/10Novel use of alkyl phosphate esters
1562010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1572010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1582010030808212/09/10Dispensing device
1592010031170612/09/10Method of treatment of allergic rhinitis
1602010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1612010030382112/02/10Immunoglobulins
1622010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1632010030512712/02/10Novel compounds
1642010030516612/02/10Novel compounds
1652010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1662010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1672010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1682010027590911/04/10Actuator for an inhaler
1692010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1702010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1712010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1722010025619910/07/10Crystalline form of an antimalarial compound
1732010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1742010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1752010022418509/09/10Actuator for an inhaler
1762010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1772010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1782010021683708/26/10Glycine transport inhibitors
1792010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1802010020325608/12/10Method and apparatus for the application of powder material to substrates
1812010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1822010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1832010019767908/05/10Compounds
1842010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1852010019076407/29/10Novel compounds
1862010018477007/22/10Compounds
1872010018499607/22/10Process of amide formation
1882010017569807/15/10Capsule
1892010017406507/08/10Compounds
1902010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1912010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1922010014401606/10/10Apparatus for the disruption of animal cells
1932010014475506/10/10Novel compounds
1942010014482906/10/10Novel receptor antagonists and their methods of use
1952010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1962010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1972010013735306/03/10Tricyclic compounds as antibacterials
1982010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1992010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
2002010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
2012010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2022010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2032010011379605/06/10Indole derivatives as s1p1 receptor
2042010010565204/29/10Purines as cysteine protease inhibitors
2052010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2062010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2072010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2082010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2092010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2102010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2112010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2122010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2132010006816603/18/10Oral composition comprising dimethicone copolyol
2142010006940903/18/10"novel compounds"
2152010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2162010005905203/11/10Sheet driver for use in a drug dispenser
2172010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2182010005650203/04/10Compounds
2192010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2202010005659503/04/10Pyrazole derivatives as p2x7 modulators
2212010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2222010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2232010002969902/04/10Matrix metalloproteinase inhibitors
2242010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2252010001637101/21/10Indole compounds
2262010001002101/14/10Novel compounds
2272010000052801/07/10Manifold for use in medicament dispenser
2282010000052901/07/10Manifold for use in medicament dispenser
2292010000342001/07/10Medicament dispenser
2302010000423001/07/10Azatricyclic compounds and their use
2312010000424001/07/10Indole compounds
2322009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2332009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2342009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2352009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2362009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2372009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2382009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2392009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2402009029874212/03/09Process for manufacturing lactose
2412009029114611/26/09Process for manufacturing lactose
2422009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2432009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2442009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2452009027035510/29/09Compounds
2462009027051010/29/09Glycine transport inhibitors
2472009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2482009023644509/24/09Fluid dispenser
2492009023984609/24/09Novel compounds


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo